# Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer

> **NCT00040560** · PHASE1 · UNKNOWN · sponsor: **Copharos**

## Conditions studied

- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Brain Neoplasms
- Metastases, Neoplasm

## Interventions

- **DRUG:** 111In-DAC
- **PROCEDURE:** Diagnostic

## Key facts

- **NCT ID:** NCT00040560
- **Lead sponsor:** Copharos
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040560, "Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00040560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*